- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
- Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
- Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
- Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
- Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
More ▼
Key statistics
On Friday, Vera Therapeutics Inc (VERA:NMQ) closed at 36.70, -27.73% below its 52-week high of 50.78, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.67 |
---|---|
High | 37.96 |
Low | 36.19 |
Bid | 36.28 |
Offer | 40.00 |
Previous close | 36.84 |
Average volume | 629.67k |
---|---|
Shares outstanding | 54.70m |
Free float | 50.36m |
P/E (TTM) | -- |
Market cap | 2.01bn USD |
EPS (TTM) | -2.04 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 21:00 BST.
More ▼